The effects of congenital brain serotonin deficiency on responses to chronic fluoxetine

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• The role of serotonin (5-HT) deficiency and hippocampal neurogenesis in antidepressant mechanisms is debated.
• Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine (FLX) are standard depression treatments.
• Congenital serotonin deficiency may alter responses to antidepressants.

Purpose of the Study:

• To investigate the effects of chronic fluoxetine (FLX) in a mouse model with congenital serotonin (5-HT) deficiency (Tph2KI mice).
• To determine if restoring 5-HT levels or inducing supra-physiological levels is necessary for FLX's antidepressant-like effects.
• To assess the impact of 5-HT deficiency on FLX-induced neurogenesis and anxiolytic-like behaviors.

Main Methods:

• Utilized tryptophan hydroxylase 2 (Tph2) knock-in (Tph2KI) mice, a model of congenital 5-HT deficiency.
• Administered chronic fluoxetine (FLX) and 5-hydroxytryptophan (5-HTP) to Tph2KI and wild-type mice.
• Assessed behavioral (novelty suppressed feeding), neurochemical, and neurogenic outcomes.

Main Results:

• Congenital 5-HT deficiency blunted several molecular, cellular, and behavioral effects of FLX, even when FLX normalized 5-HT levels.
• Supra-physiological 5-HT levels, not just reversal of deficiency, appear necessary for many FLX antidepressant-like effects.
• Co-administration of FLX and 5-HTP rescued the anxiolytic-like effect in novelty suppressed feeding in Tph2KI mice, without inducing neurogenesis.

Conclusions:

• Congenital brain 5-HT deficiency reduces FLX efficacy.
• Supplementation with 5-HTP can restore some antidepressant-like responses in serotonin-deficient states.
• FLX-induced anxiolytic effects in this model are not solely mediated by neurogenesis, especially in 5-HT deficient animals.